Jinyu 生物股份
19 significant filings since 29 May 2026: 1 on share pledge, 12 on buyback and 3 on dividend, and 3 other kinds. The latest, on 8 Sep 2026: 生物股份关于股份回购实施结果暨股份变动的公告. On 6 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 50.60% to 80.39% from the same period a year earlier.
自 29 May 2026 起有 19 份重大公告：share pledge 1 份、buyback 12 份、dividend 3 份，另有 3 类。最新一份（8 Sep 2026）：生物股份关于股份回购实施结果暨股份变动的公告。6 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 50.60% 至 80.39%。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥125亿 | ¥39亿 | Highest of 12 · 12 家中第 1 高 | |
| Trailing P/E 市盈率 | 87.2x | 48.6x | 3rd highest of 9 · 9 家中第 3 高 | |
| P/B 市净率 | 2.3x | 2.1x | 6th highest of 12 · 12 家中第 6 高 | |
| Revenue Growth 营收增速 | 22.1% | 0.0% | Highest of 12 · 12 家中第 1 高 | |
| Profit Growth 净利增速 | 72.3% | -36.2% | 3rd highest of 12 · 12 家中第 3 高 | |
| Gross Margin 毛利率 | 53.9% | 38.8% | 5th highest of 12 · 12 家中第 5 高 | |
| Net Margin 净利率 | 14.7% | 8.3% | 3rd highest of 12 · 12 家中第 3 高 | |
| Return on Equity 净资产收益率 | 1.9% | 2.3% | 6th lowest of 12 · 12 家中第 6 低 | |
| Debt to Assets 资产负债率 | 16.5% | 23.4% | 6th lowest of 12 · 12 家中第 6 低 | |
| Grade Score 评级得分 | 62 | 54 | 3rd highest of 12 · 12 家中第 3 高 |
Statement figures are for the period to 30 Jun 2026, filed by 12 of 12 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，12 家同业中 12 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Jinyu 生物股份 | ¥125亿 | 87.2x | 2.3x | 22.1% | 14.7% | 1.9% | C |
| Tianjin Ringpu Bio-Technology 瑞普生物 | ¥77亿 | 22.2x | 1.6x | 0.8% | 12.9% | 4.3% | C |
| China Animal Husbandry 中牧股份 | ¥68亿 | 48.6x | 1.2x | 13.5% | 2.3% | 0.9% | D |
| Keqian Biology 科前生物 | ¥57亿 | 18.1x | 1.4x | -23.3% | 30.7% | 2.8% | C |
| Jinhe Biotechnology 金河生物 | ¥43亿 | 210.0x | 1.7x | 4.1% | 9.3% | 5.7% | C |
| Wuhan HVSEN Biotechnology 回盛生物 | ¥42亿 | 12.3x | 1.8x | 5.2% | 23.9% | 9.1% | C |
| Pulike 普莱柯 | ¥35亿 | 24.1x | 1.4x | -12.2% | 13.0% | 3.0% | C |
| Lifecome Biochemistry 绿康生化 | ¥35亿 | — | 49.1x | -15.7% | 2.8% | 10.9% | C |
| Shen Lian Biomedical 申联生物 | ¥34亿 | — | 2.5x | -8.1% | -18.2% | -1.4% | D |
| Winsunbio 永顺生物 | ¥18亿 | 64.0x | 2.7x | -28.1% | 7.3% | 0.9% | D |
| Drive 驱动力 | ¥11亿 | 460.9x | 4.6x | -0.8% | -1.6% | -0.2% | D |
| Dayu Biological 大禹生物 | ¥6.96亿 | — | 2.9x | 15.7% | -36.9% | -10.6% | E |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。